Amyloidosis: open trials in Canada

• NCT06128629

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  Trial Treatment · Phase 3 · Intellia Therapeutics

  Alberta Health Services - University of Calgary, Calgary · McGill University Health Centre, Montreal · Montreal Heart Institute, Montreal · University Health Network, Toronto General Hospital, Toronto · Vancouver Coastal Health Research Institute, Vancouver

  Registry updated 2026-11-04

• NCT07207811

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  Trial Treatment · Phase 3 · Novo Nordisk A/S

  University Of Calgary, Calgary · Health Sciences North Research Institute-Advanced Medical Research Institute of Canada, Greater Sudbury · Nova Scotia Health Authority, Halifax · Cardio Health Clinical Trials, Hamilton · Cardio Health Clinical Trials, Kitchener · London Health Sciences Centre, University Hospital, London · Cardio Health Clinical Trials, Mississauga · University of Ottawa - Heart Institute (UOHI) (Institut de Cardiologie de L'Universite d'Ottawa), Ottawa · Hotel-Dieu de Quebec, Québec · CIUSSS du Saguenay Lac-Saint-Jean, Québec · Centre Hospitalier Regional De Rimouski, Rimouski · Cardio Health Clinical Trials, Scarborough Village · Riverside Cardiology and Diagnostic Imaging, Toronto · Vancouver General Hospital, Vancouver

  Registry updated 2026-10-21

• NCT07052903

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  Trial Treatment · Phase 3 · Alnylam Pharmaceuticals

  Calgary · London · Toronto · Vancouver

  Registry updated 2026-10-20

• NCT07223203

  TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  Trial Treatment · Phase 3 · Alnylam Pharmaceuticals

  Vancouver

  Registry updated 2026-10-08

• NCT06465810

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  Research · AstraZeneca

  Halifax · London · Montreal · Rimouski · Toronto · Vancouver

  Registry updated 2026-09-23

• NCT07654855

  Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations

  Research · AstraZeneca

  Vancouver

  Registry updated 2026-09-14

• NCT06355934

  OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

  Research · AstraZeneca

  Calgary

  Registry updated 2026-09-09

• NCT06563895

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  Trial Treatment · Phase 3 · Eidos Therapeutics, a BridgeBio company

  University Of Calgary, Calgary · St. Michael's Hospital, Toronto · University of British Columbia, Vancouver

  Registry updated 2026-08-04

• NCT07081646

  A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

  Trial Treatment · Phase 1/2 · Alexion Pharmaceuticals, Inc.

  Calgary · Toronto

  Registry updated 2026-07-02

• NCT05667493

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  Trial Treatment · Phase 3 · Ionis Pharmaceuticals, Inc.

  University Of Calgary, Calgary · University Hospital - London Health Sciences Centre, London · Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal · Hôpital régional de Rimouski, Rimouski · Toronto General Hospital, Toronto · Gordon and Leslie Diamond Health Care Centre, Vancouver

  Registry updated 2026-04-17

All Amyloidosis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error